Abstract

Despite multiple studies evaluating various therapeutic agents, few have emerged as superior agents for the management of alcohol use disorders. As a result, off-label agents, including gabapentin, are being utilized more frequently in clinical practice. Gabapentin has gained popularity as one of the more commonly studied off-label agents. Gabapentin's relatively low abuse potential, side effect profile, and limited hepatic metabolism make it an attractive option compared with benzodiazepines and other anticonvulsants. Several randomized, placebo- and active-controlled trials have evaluated off-label use of gabapentin for the treatment of alcohol detoxification and dependence. Study results and interpretation from the more robust available data are summarized within this article.

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract